US Stock Movement: Tempus AI surged on October 20 with AI pre-screening for non-small cell lung cancer and biomarker detection
Bitget异动解读2026/10/20 16:45Tempus AI Soars on October 20: Analysis
Keywords: AI pre-screening for non-small cell lung cancer, biomarker testing
On October 19, Tempus announced results from an AI-assisted pre-screening study for advanced non-small cell lung cancer: analyzing 60,459 cases and involving 12 types of biomarkers, with all sensitivities exceeding 80% using standard H&E pathological images, and several surpassing 90%. The study results will be presented at the 2026 European Society for Medical Oncology Congress.
(Disclaimer: This content is generated by AI technology summarizing public information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Movement: Zenas BioPharma surged on October 20, driven by INDIGO Phase III data and Obeximab.
Netflix plans to expand its advertising business to 15 new countries by 2027
Swiss gold exports increased by 6% in September, with exports to the UK surging.
Brent crude main futures contract surpasses the $109/barrel mark
Crypto prices
More
